Category Archives: Glucose Monitoring

Novo Sues Orbicular Pharmaceuticals Over Generic Saxenda; Sema Ph2 NASH Trial Disappoints; Kerendia Receives New Recommendations from ADA; Sanofi Cuts Insulin Price and Partners with Direct Relief; Novartis to Cut 8,000 Jobs Worldwide; Lifescan Publishes Connected BGM RWE

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Bayer, Sanofi, Novartis, and Lifescan. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Novo and Echosens Partnership to Increase NASH Awareness; GlucoTrack to Initiate First In-human Clinical Study for GlucoTrack 2.0

Two cardiometabolic-related news items have been observed: Novo Nordisk and Echosens announced a partnership to increase awareness and advance early diagnosis of NASH; and GlucoTrack, formerly known as Integrity Applications, provided development updates on its Gen 2 non-invasive glucose monitor (press release). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Senseonics Eversense E3 CGM Receives CE Mark; Tandem Appoints Two New Members to Board of Directors; Akero Announces Financing Transactions with Pfizer and Hercules Capital

Three cardiometabolic-related news items have been observed: Senseonics announced it has received CE Mark for the next-generation Eversense E3 CGM system; Tandem announced the appointment of two new directors to its board; and Akero Therapeutics announced two financing transactions with Pfizer and Hercules Capital. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Updated Abbott vs. Dexcom CGM Tale-of-the-tape Analysis

The CGM market continues to be dynamic, most recently with Abbott’s Libre 3 receiving FDA approval (previous FENIX insight) and Dexcom’s G7 approval right around the corner. Both companies represented well at ATTD and ADA, and momentum should continue into EASD (Sept 19-23). With Dexcom’s G7 US approval anticipated soon, FENIX updated its tale-of-the-tape comparative analysis between Abbott’s Libre 2 and 3 vs. Dexcom’s G6 and G7 CGM systems.

This content is for Read Less members only.
Register

Already a member? Log in here

Thoughts after ATTD and ADA 2022

Now that we’re on the other side of ADA 2022, FENIX provides provocative thoughts below on various items in the cardiometabolic space. Included are thoughts about Lilly, Novo, Sanofi, Dexcom, Abbott, Medtronic, Bigfoot, and Beta Bionics.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2022 Key Press Releases (June 5-6)

On the third and fourth days of ADA 2022, seven cardiometabolic-related news items were observed from Abbott, Bigfoot, BI/Lilly, Intercept, Amarin, Vertex, and Sernova. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2022 Key Press Releases (June 3)

On the first day of ADA 2022, four cardiometabolic-related news items were observed from Novo, Abbott, Dario, and Zealand. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott Announces Libre 3 Clearance; Lexicon Resubmits Sota NDA; Dexcom Denies Insulet Acquisition Speculation

Three cardiometabolic-related news items have been observed: Abbott issued a press release addressing the recent FDA clearance of its Freestyle Libre 3 (view press release); Lexicon announced it has resubmitted the sota HF NDA; and Dexcom issued a press release responding to recent media and market speculation that the company was in the process of acquiring Insulet (view press release). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott’s Libre 3 FDA Approved

Today, FDA updated its 510(k) website which shows that Abbott’s Libre 3 received FDA approval on Thursday, May 26, 2022. Although no Abbott press release has been observed, likely due to the US Memorial Day holiday weekend, Abbott is expected to issue a press release on Tuesday May 31 and have a full promotional booth at the upcoming ADA congress in New Orleans (June 3-7).

This content is for Read Less members only.
Register

Already a member? Log in here

Bigfoot Hires Matt Rainville as CCO; Medtronic CY Q1 ’22 (FY Q4 ’22) Earnings Update; Pfizer’s NASH Combo Receives Fast Track Designation; ReShape and OpenLoop Collaboration for Virtual Weight Loss Coaching Program

A series of cardiometabolic-related news items have been observed: Bigfoot announced it has appointed Matt Rainville (view LinkedIn) as CCO; Medtronic hosted its CY Q1 ’22 (FY Q4 ’22) earnings call (press release; slides); Pfizer announced FDA granted Fast Track designation to Pfizer’s ervogastat+clesacostat combination therapy for NASH; and ReShape LifeSciences and OpenLoop announced a collaboration for a nationwide launch of reshapecare. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here